• Home
  • How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational study
Birkeland K, Bode gard J, Norhammar A, Kuiper J, Georgiado E, Beekman-Hendriks W, Thuresson M, Pignot M, Herings R, Kooy A. Diabetes Obes Metab. 2018 21 968-974.